Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Avelox moxifloxacin: Phase II data

In a Phase II trial in 344 evaluable patients, moxifloxacin plus rifampin, pyrazinamide and ethambutol missed the primary endpoint of

Read the full 202 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE